Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jul 14, 2021 11:38am
146 Views
Post# 33542407

RE:RE:The “new strategy”

RE:RE:The “new strategy” They cannot invent news and publish press releases out of nothing. This period reminds me of the long wait for ibalizumab (Trogarzo) approval. It was long, with an added delay by the FDA, we were complaining that the market was not recognizing the fact that the approval was almost sure. Then, the approval finally came, and the stock price rose significantly.

We all know what happened after that, and it explains a big part of the actual skepticism by the market and why nothing is given to Thera in advance. A company has to live with its history. I am hiting on that nail over and over here and no one seems willing to acknowledge that basic fact. When a company wants to hire somebody, they ask for a resume, and they look at the past to make a judgement. The history of Thera is its resume to investors. They cannot invent a new one. But the day Thera will add a bright success in its resume, the market will take notice and many will chose the company as a good investing opportunity.

At this point, Thera is a company for investors trusting the management and the board, and that are making a positive projection about oncology, or willing to trust qualified people making that positive projection. But it remains a speculative stock, with the added benefit of having two approved drugs and second program in NASH in the case positive projections on oncology would end up being wrong, which is a real possibility. A projection is not a certainty. All that to say that we are in the middle of the summer in a waiting game, and in this case, the longer we wait, the better it is on the oncology side.


mikeq113 wrote: I just don't understand their logic as it pertains to marketing, communications and the investment community at all. 

They just went out and presumably spent a decent amount of money to get LSA involved and the only signs of this have been a revamped website (long overdue) and a KOL event that created some buzz and a short-term bounce in the stock price followed by defeaning silence for three weeks leading up to an earnings call, which is highly likely to receive either a collective shrug from the market or continue a slow and steady slide back to the mid $3s.

Why even bother to hold a KOL webinar if you're not planning to follow that with steady PR's or some investor engagement further pushing an exciting narrative around the cancer trials OR use that to get people interested before announcing your finalized and hopefully *harmonized* Phase III NASH trial protocol??


<< Previous
Bullboard Posts
Next >>